ACRV (Acrivon Therapeutics) Current Accrued Expense: $6.23 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACRV Acrivon Therapeutics Inc ACRV
34 GF Score
Price $2.06
! 3 Warning Signs
View Full Analysis

What is Acrivon Therapeutics Current Accrued Expense?

Acrivon Therapeutics ACRV -4.41% 34 Current Accrued Expense is $6.23 Mil as of Jun. 2026. GuruFocus rates ACRV with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Acrivon Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2026 was $6.23 Mil.

Acrivon Therapeutics's quarterly Current Accrued Expense declined from Dec. 2025 ($6.66 Mil) to Mar. 2026 ($6.57 Mil) and declined from Mar. 2026 ($6.57 Mil) to Jun. 2026 ($6.23 Mil).

Acrivon Therapeutics's annual Current Accrued Expense increased from Dec. 2023 ($3.52 Mil) to Dec. 2024 ($9.94 Mil) but then declined from Dec. 2024 ($9.94 Mil) to Dec. 2025 ($6.66 Mil).

Acrivon Therapeutics Current Accrued Expense Related Terms

Acrivon Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Acrivon Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acrivon Therapeutics Current Accrued Expense Chart

Acrivon Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 0.55 2.16 3.52 9.94 6.66

Acrivon Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.94 8.32 6.66 6.57 6.23
ACRV
34GF Score
Acrivon Therapeutics Inc ACRV
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acrivon Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $6.23 Mil mean?
Acrivon Therapeutics (ACRV) has a Current Accrued Expense of $6.23 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Acrivon Therapeutics and its competitors.
Is Acrivon Therapeutics' Current Accrued Expense too high?
Acrivon Therapeutics' current Current Accrued Expense is $6.23 Mil. Overall, Acrivon Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Acrivon Therapeutics' Current Accrued Expense compare to SPRO and BSEM?
Acrivon Therapeutics' Current Accrued Expense of $6.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Acrivon Therapeutics and its competitors. Acrivon Therapeutics's current Current Accrued Expense is $6.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrivon Therapeutics stock overvalued right now?
Acrivon Therapeutics (ACRV) has a current Current Accrued Expense of $6.23 Mil. The current Current Accrued Expense is $6.23 Mil. Acrivon Therapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Acrivon Therapeutics (ACRV), the current Current Accrued Expense is $6.23 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acrivon Therapeutics Business Description

Address 480 Arsenal Way, Suite 100, Watertown, MA, USA, 02472
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
34GF Score

Get the complete analysis for ACRV

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.06
Price